Jasper Therapeutics’ (JSPR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $65.00 target price on the stock.

Several other equities analysts have also recently commented on JSPR. BTIG Research initiated coverage on Jasper Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $90.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Evercore ISI restated an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. Royal Bank of Canada cut their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Finally, Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They set a “buy” rating and a $86.00 price objective for the company. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $74.86.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR traded up $0.06 during mid-day trading on Thursday, reaching $19.96. The company had a trading volume of 2,084 shares, compared to its average volume of 167,196. The stock’s 50 day moving average is $19.34 and its 200-day moving average is $21.21. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The stock has a market capitalization of $300.68 million, a PE ratio of -3.53 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. On average, sell-side analysts anticipate that Jasper Therapeutics will post -4.16 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of large investors have recently added to or reduced their stakes in JSPR. Wolff Wiese Magana LLC bought a new position in shares of Jasper Therapeutics in the third quarter valued at $59,000. American Century Companies Inc. increased its position in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the last quarter. Rhumbline Advisers bought a new stake in Jasper Therapeutics in the second quarter valued at approximately $300,000. Bank of New York Mellon Corp bought a new position in shares of Jasper Therapeutics during the 2nd quarter worth approximately $740,000. Finally, Virtu Financial LLC acquired a new stake in Jasper Therapeutics during the first quarter worth approximately $306,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.